Intrathecal baclofen in the treatment of spasticity, dystonia and vegetative disorders.
Baclofen (beta-p-chlorophenyl-GABA) binds to a number of spinal and cerebral sites and depresses the excitability of motor neurons. Intrathecal administration induces much higher CSF concentrations compared to the limited passage through the blood-brain barrier after oral administration. The development of reliable implanted pumps allows long-term intrathecal baclofen treatment (ITB). Baclofen is mainly an antispastic drug and the main indication of ITB is generalized lower limb spasticity in spinal cord injury and multiple sclerosis. The side-effects are due to either drug over-dose or withdrawal and to malfunctions of the implanted device (disconnections of the catheter, infections, etc.). Large numbers of patients have been treated over the past twenty years. More recently, baclofen has been used in the treatment of spasticity of cerebral origin, and in the treatment of other motor disorders, mainly dystonia. The results in cerebral palsy are promising and ITB's role will probably grow in the management of the movement disorders of these children. Further studies are required on the exact site of action, on the possible association with other drugs, especially clonidine and on the development of sustained release formulations.
Richard
I
I
Département de Médecine Physique et de Réadaptation, Faculté de Médecine, Université d'Angers, Angers, France. isabelle.richard@univ-angers.fr
Menei
P
P
D001418:Baclofen / Q000627:therapeutic use*; D004421:Dystonia / Q000188:drug therapy*; D006801:Humans; D007278:Injections, Spinal / Q000379:methods; D009125:Muscle Relaxants, Central / Q000627:therapeutic use*; D009128:Muscle Spasticity / Q000188:drug therapy* / Q000209:etiology; D018458:Persistent Vegetative State / Q000188:drug therapy*
D009125:Muscle Relaxants, Central; D001418:Baclofen